GSK (GSK) Competitors GBX 1,423.65 +8.15 (+0.58%) As of 06:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock GSK vs. AZN, SOPH, ITH, HCM, GRI, INDV, SLS, ERGO, BMY, and SLNShould you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Sophos Group plc (SOPH.L) (SOPH), Ithaca Energy (ITH), HUTCHMED (HCM), Grainger (GRI), Indivior (INDV), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Bloomsbury Publishing (BMY), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. GSK vs. AstraZeneca Sophos Group plc (SOPH.L) Ithaca Energy HUTCHMED Grainger Indivior Standard Life UK Smaller Companies Trust Ergomed Bloomsbury Publishing Silence Therapeutics AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Is AZN or GSK a better dividend stock? AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.2%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.2%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do analysts rate AZN or GSK? AstraZeneca presently has a consensus price target of GBX 6,303.50, suggesting a potential downside of 40.00%. GSK has a consensus price target of GBX 1,862.50, suggesting a potential upside of 30.83%. Given GSK's higher possible upside, analysts plainly believe GSK is more favorable than AstraZeneca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67GSK 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is AZN or GSK more profitable? AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.Company Net Margins Return on Equity Return on Assets AstraZeneca13.01% 17.76% 7.68% GSK 8.02%18.08%9.56% Which has higher earnings & valuation, AZN or GSK? AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstraZeneca£66.95B3.02£8.71B£364.8328.80GSK£31.14B1.86£2.50B£61.9123.00 Which has more risk and volatility, AZN or GSK? AstraZeneca has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Does the media refer more to AZN or GSK? In the previous week, GSK had 2 more articles in the media than AstraZeneca. MarketBeat recorded 4 mentions for GSK and 2 mentions for AstraZeneca. GSK's average media sentiment score of 0.61 beat AstraZeneca's score of 0.33 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of AZN or GSK? 51.0% of AstraZeneca shares are held by institutional investors. Comparatively, 45.3% of GSK shares are held by institutional investors. 0.0% of AstraZeneca shares are held by insiders. Comparatively, 1.6% of GSK shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor AZN or GSK? AstraZeneca received 774 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.78% of users gave AstraZeneca an outperform vote while only 50.37% of users gave GSK an outperform vote. CompanyUnderperformOutperformAstraZenecaOutperform Votes186563.78% Underperform Votes105936.22% GSKOutperform Votes109150.37% Underperform Votes107549.63% SummaryAstraZeneca beats GSK on 10 of the 19 factors compared between the two stocks. Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GSK vs. The Competition Export to ExcelMetricGSKDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£57.77B£94.49B£5.43B£2.68BDividend Yield4.25%2.47%5.22%4.96%P/E Ratio23.0023.6026.79134.50Price / Sales1.86162.58394.72216,044.87Price / Cash8.1517.5938.2528.03Price / Book4.323.026.863.79Net Income£2.50B£3.43B£3.22B£5.88B7 Day Performance4.68%1.19%6.83%7.72%1 Month Performance7.60%1.27%13.73%29.23%1 Year Performance-18.93%-8.60%18.22%118.50% GSK Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GSKGSK3.6117 of 5 starsGBX 1,423.65+0.6%GBX 1,862.50+30.8%-20.3%£57.77B£31.14B23.0070,212High Trading VolumeAZNAstraZeneca1.3154 of 5 stars£102.72+0.3%GBX 6,303.50-38.6%-13.9%£197.64B£66.95B28.1683,500Gap DownSOPHSophos Group plc (SOPH.L)N/AN/AN/AN/A£2.99B£726.90M341.41520ITHIthaca EnergyN/AGBX 140-0.1%N/A+9.5%£2.92B£3.55B15.99220Trending NewsHCMHUTCHMEDN/AGBX 214-3.3%N/A-37.3%£2.32B£771.01M-54.621,760News CoverageHigh Trading VolumeGRIGrainger2.9758 of 5 starsGBX 216.50-0.5%GBX 317.50+46.7%-11.1%£1.60B£276.05M-1,443.33372Earnings ReportDividend IncreaseINDVIndivior1.7209 of 5 starsGBX 845.50+0.6%GBX 1,650+95.2%-35.9%£1.32B£1.40B-701.041,000SLSStandard Life UK Smaller Companies TrustN/AN/AN/AN/A£715.41M£222.48M3.3710ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386BMYBloomsbury Publishing3.1142 of 5 starsGBX 627.62+1.2%GBX 825+31.4%+6.2%£506.45M£382.40M13.4334,300News CoverageSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume Related Companies and Tools Related Companies AZN Competitors SOPH Competitors ITH Competitors HCM Competitors GRI Competitors INDV Competitors SLS Competitors ERGO Competitors BMY Competitors SLN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:GSK) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.